Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Kidney Int. 2013 Jun 5;84(6):1166–1175. doi: 10.1038/ki.2013.209

Figure 4.

Figure 4

Late tubulointerstitial fibrosis in wild type and PAI-1−/− mice. (A) Tubulointerstitial fibrosis in wild type mice at day 14 after UUO was significantly increased by thymosin β4 plus POP inhibitor (Tβ4+POPi) but was significantly decreased by thymosin β4 alone or Ac-SDKP (Control, n=10; Tβ4+POPi, n=7; Tβ4 n=5; Ac-SDKP, n=6; *p<0.05 vs control). (B) Tubulointerstitial fibrosis in PAI-1−/− mice at day 14 after UUO was significantly decreased by Ac-SDKP. In contrast to WT mice, neither thymosin β4 plus POP inhibitor nor thymosin β4 alone affected fibrosis (Control, n=8; Tβ4+POPi, n=8; Tβ4 n=5; Ac-SDKP, n=7; *p<0.05 vs control).